NIP
CABA icon

Nicholas Investment Partners’s Cabaletta Bio CABA Stock Holding History

Nicholas Investment Partners’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-54,586
Closed -$1.24M – 205
2023
Q4 		$1.24M Buy
+54,586
New +$918K 0.15% 155

Other funds holding CABA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Nicholas Investment Partners's CABA Position: Q1 2024 in Review

Nicholas Investment Partners sold out of Cabaletta Bio (CABA) in Q1 2024, closing a stake of 54,586 shares — an estimated $1.24M sold.

Nicholas Investment Partners first reported a position in CABA in Q4 2023 and held it in 1 quarter. The position peaked at $1.24M in Q4 2023. 159 funds tracked by Wall St. Rank hold CABA as of Q1 2024.

  • Nicholas Investment Partners reported no remaining Cabaletta Bio position as of Q1 2024 after selling out during the quarter.
  • Nicholas Investment Partners sold 54,586 Cabaletta Bio shares in Q1 2024, an estimated $1.24M.
  • Nicholas Investment Partners first reported a position in Cabaletta Bio in Q4 2023 and held it in 1 quarter.
  • Nicholas Investment Partners's Cabaletta Bio position peaked at $1.24M in Q4 2023.
  • 159 funds tracked by Wall St. Rank held Cabaletta Bio as of Q1 2024.

Based on Nicholas Investment Partners's 13F filing for Q1 2024, filed 14 May 2024.